Abstract
We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers. ADVAX or placebo was administered intramuscularly at months 0, 1 and 3 to 45 healthy volunteers not at high risk for HIV-1. Three dosage levels [0.2 mg (low), 1.0 mg (mid), and 4.0 mg (high)] were tested. Twelve volunteers in each dosage group were assigned to receive ADVAX and three to receive placebo in a double-blind design. Subjects were followed for local and systemic reactogenicity, adverse events, and clinical laboratory parameters. Study follow up was 18 months. Humoral immunogenicity was evaluated by anti-gp120 binding ELISA. Cellular immunogenicity was assessed by a validated IFNgamma ELISpot assay and intracellular cytokine staining. ADVAX was safe and well-tolerated, with no vaccine-related serious adverse events. Local and systemic reactogenicity events were reported by 64% and 42% of vaccine recipients, respectively. The majority of events were mild. The IFNgamma...Continue Reading
References
Apr 3, 2001·Science·D Paydarfar, W J Schwartz
Jun 8, 2001·Science·R R AmaraH L Robinson
May 27, 2003·Nature Medicine·Samuel J McConkeyAdrian V S Hill
Nov 27, 2004·Journal of Virology·Linqi ZhangDavid D Ho
Feb 26, 2005·Journal of Virology·Shanmugalakshmi SadagopalHarriet L Robinson
Apr 28, 2006·Journal of Virology·Nilu GoonetillekeAndrew J McMichael
May 27, 2006·Virology·Dennis EllenbergerSalvatore Butera
Jul 13, 2006·AIDS Research and Human Retroviruses·M J MulliganUNKNOWN NIH/NIAID/DAIDS HIV Vaccine Trials Network
Nov 17, 2006·Social Science & Medicine·Yan XiaoSten H Vermund
Nov 17, 2006·The Journal of Infectious Diseases·Barney S GrahamUNKNOWN Vaccine Research Center 004 Study Team
Mar 10, 2007·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Liu WeiJ Brooks Jackson
Mar 30, 2007·Vaccine·Andrew T CatanzaroUNKNOWN VRC 007 Study Team
Oct 27, 2007·Expert Opinion on Biological Therapy·Alain LuxembourgDrew Hannaman
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jean D BoyerDavid B Weiner
Jan 16, 2008·The Journal of Experimental Medicine·Alexandre HarariGiuseppe Pantaleo
Jan 23, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Zhiwei ChenDavid D Ho
Jan 23, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Yaoxing HuangDavid D Ho
Mar 11, 2008·Vaccine·Yaoxing HuangMoriya Tsuji
May 27, 2008·Vaccine·Sheena McCormackJonathan Weber
Nov 18, 2008·Lancet·Susan P BuchbinderUNKNOWN Step Study Protocol Team
Nov 18, 2008·Lancet·M Juliana McElrathUNKNOWN Step Study Protocol Team
Dec 17, 2008·Vaccine·Norman G JonesHuyen Cao
Dec 19, 2008·Clinical and Vaccine Immunology : CVI·Mark J BoazJill Gilmour
Mar 27, 2009·Journal of Virology·Petra MooijJonathan L Heeney
Dec 1, 2009·AIDS Research and Human Retroviruses·Vadakkuppatu Devasenapathi RamanathanPatricia Fast
Citations
May 24, 2011·PloS One·Sandhya VasanDavid D Ho
Oct 25, 2011·PloS One·Lycias ZembeClive M Gray
Feb 19, 2013·PloS One·Sanjay MehendaleVadakkuppatu Devasenapathi Ramanathan
Oct 1, 2013·Virology Journal·Ye LiuYiming Shao
Jun 8, 2013·Current Opinion in HIV and AIDS·Jean-Louis ExclerNina D Russell
Sep 9, 2010·Expert Review of Vaccines·Robert M ParisNelson L Michael
Nov 12, 2015·Vaccines·Diana Boraschi, Paola Italiani
Nov 25, 2011·Journal of Pharmaceutical Sciences·Jamie BetkerThomas J Anchordoquy
May 11, 2013·Journal of Bioscience and Bioengineering·Bo SunWei Kong
Sep 6, 2011·Drug Discovery Today·Chintan ChhatbarSunit Kumar Singh
May 3, 2011·Current Opinion in Immunology·Niranjan Y Sardesai, David B Weiner
Jan 5, 2011·Vaccine·Viraj KulkarniGeorge N Pavlakis
May 11, 2010·Vaccine·Vainav PatelGeorge N Pavlakis
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Kristin HollisterAlexander Dent
Apr 15, 2015·Gene Therapy·O RiedeC Juhls
May 29, 2012·Human Vaccines & Immunotherapeutics·Claudia SchmidtPatricia E Fast
Aug 17, 2012·Human Vaccines & Immunotherapeutics·Rashmi JalahBarbara K Felber
Aug 8, 2012·PloS One·Michael C KeeferJean-Louis Excler
Oct 11, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Madhura MukhopadhyayLisa A Chakrabarti
Feb 12, 2012·World Journal of Virology·Maria TrovatoPiergiuseppe De Berardinis
Jan 25, 2013·Clinical and Vaccine Immunology : CVI·Peter HayesDagna Laufer
Mar 29, 2019·PloS One·Sivasankaran Munusamy PonnanHanna Elizabeth Luke
Aug 21, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gunnveig GrodelandBjarne Bogen
May 3, 2013·The Journal of Clinical Investigation·Jingying ZhouZhiwei Chen
Feb 26, 2020·PloS One·Sivasankaran Munusamy PonnanLuke Elizabeth Hanna
Jan 11, 2021·Advanced Drug Delivery Reviews·Deborah PushparajahRoderick A Slavcev
Apr 24, 2021·Frontiers in Immunology·Sivasankaran Munusamy PonnanLuke Elizabeth Hanna
Jun 25, 2015·Microbiology Spectrum·John S Tregoning, Ekaterina Kinnear
Jun 15, 2021·PLoS Pathogens·Yik Chun WongZhiwei Chen